Ferroptosis: an emerging strategy for managing epithelial ovarian cancer
| UDC.coleccion | Investigación | |
| UDC.departamento | Fisioterapia, Medicina e Ciencias Biomédicas | |
| UDC.departamento | Bioloxía | |
| UDC.grupoInv | Grupo de Investigación en Terapia Celular e Medicina Rexenerativa (TCMR) | |
| UDC.grupoInv | Regulación da Expresión Xénica e Aplicacións (EXPRELA) | |
| UDC.grupoInv | Terapia Celular e Medicina Rexenerativa (INIBIC) | |
| UDC.institutoCentro | CICA - Centro Interdisciplinar de Química e Bioloxía | |
| UDC.institutoCentro | INIBIC - Instituto de Investigacións Biomédicas de A Coruña | |
| UDC.journalTitle | Biomedicine & Pharmacotherapy | |
| UDC.startPage | 118065 | |
| UDC.volume | 187 | |
| dc.contributor.author | Alarcón Veleiro, Carmen | |
| dc.contributor.author | López Calvo, Ismael | |
| dc.contributor.author | Berjawi, Lama | |
| dc.contributor.author | Lucio-Gallego, Sergio | |
| dc.contributor.author | Mato-Basalo, Rocío | |
| dc.contributor.author | Quindós-Varela, María | |
| dc.contributor.author | Lesta-Mellid, Rocío | |
| dc.contributor.author | Santamarina, Isabel | |
| dc.contributor.author | Varela Rodríguez, Sabela | |
| dc.contributor.author | Fraga Mariño. María | |
| dc.contributor.author | Quintela, Marcos | |
| dc.contributor.author | Vizoso-Vázquez, Ángel | |
| dc.contributor.author | Arufe, M.C. | |
| dc.contributor.author | Fafián-Labora, J. A. | |
| dc.date.accessioned | 2025-08-25T08:19:40Z | |
| dc.date.available | 2025-08-25T08:19:40Z | |
| dc.date.issued | 2025-04-29 | |
| dc.description | Review | |
| dc.description.abstract | [Abstract] Ferroptosis is a regulated form of cell death characterised by iron-dependent lipid peroxidation, a process intricately linked to cellular redox homeostasis. This form of cell death is induced by the accumulation of intracellular iron and the subsequent generation of reactive oxygen species (ROS), which leads to lipid peroxidation and ultimately cell death. Ferroptosis is distinct from traditional forms of cell death, such as apoptosis, and holds significant therapeutic potential, particularly in cancers harboring rat sarcoma virus (RAS) mutations, such as epithelial ovarian cancer (EOC). EOC is notoriously resistant to conventional therapies and is associated with a poor prognosis. In this review, we examine recent progress in the understanding of ferroptosis, with a particular focus on its redox biology and the complex regulatory networks involved. We also propose a novel classification system for ferroptosis modulators, grouping them into six categories (I, II, III, IV, V and VI) based on their mechanisms of action and their roles in modulating cellular redox status. By refining these categories, we aim to provide deeper insights into the role of ferroptosis in cancer biology, especially in EOC, and to identify potential therapeutic avenues. We propose that further investigation of ferroptosis in the context of redox biology could reveal novel biomarkers and therapeutic targets, offering promising strategies to overcome resistance mechanisms and improve clinical outcomes for patients with EOC and other treatment-resistant cancers. | |
| dc.description.sponsorship | J.F.L was funded by Xunta de Galicia, grant number ED481D-2021–020, Ministerio de Ciencia e Innovación (RYC2021–032567-I), funded by MCIN/AEI/10.13039/ 501100011033 and from the European Union «NextGenerationEU»/PRTR» and the InTalent program from UDC-Inditex for the research grant and the project PI23/01347, was funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. M.C.A has been funded by the project "PI20/00497" funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. J.F.L and M.C.A are funded by Xunta de Galicia (ED431F 2023/30). J.F.L. and A.V.V. were granted with “Development of research strategic actions UDC I+D+i 2021–2022: CICA-Disrupting Projects 2021SEM-A2 (FERRSEV)”. J.F.L and M.C.A were funded by projects co-financed by FINIBIC’s Call for Development and Transfer Project Grants (RESISFERRO and ENDOPROT, respectively). C.A.V was awarded with research grant from Diputación da Coruña 2023. | |
| dc.identifier.citation | Alarcón-Veleiro C, López-Calvo I, Berjawi L, Lucio-Gallego S, Mato-Basalo R, Quindos-Varela M, Lesta-Mellid R, Santamarina-Caínzos I, Varela-Rodríguez S, Fraga M, Quintela M, Vizoso-Vázquez A, Arufe MC, Fafián-Labora J. Ferroptosis: an emerging strategy for managing epithelial ovarian cancer. Biomed Pharmacother. 2025 Jun;187:118065. | |
| dc.identifier.doi | 10.1016/j.biopha.2025.118065 | |
| dc.identifier.issn | 0753-3322 | |
| dc.identifier.uri | https://hdl.handle.net/2183/45648 | |
| dc.language.iso | eng | |
| dc.publisher | Elsevier | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI20%2F00497/ES/TERAPIA CELULAR CON MICRO ARN Y VESICULAS EXTRACELULARES PARA EL TRATAMIENTO DE LA INFLAMACION CRONICA EN UN MODELO DE OA. (TERAPIA LIBRE DE CELULAS)/ | |
| dc.relation.uri | https://doi.org/10.1016/j.biopha.2025.118065 | |
| dc.rights | Attribution 4.0 International | en |
| dc.rights.accessRights | open access | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | Epithelial ovarian cancer | |
| dc.subject | Ferroptosis | |
| dc.subject | Redox biology | |
| dc.title | Ferroptosis: an emerging strategy for managing epithelial ovarian cancer | |
| dc.type | journal article | |
| dc.type.hasVersion | VoR | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 9a24b244-dd15-42a4-81de-9d5064152fb4 | |
| relation.isAuthorOfPublication | bc4e93d7-b3bb-4362-9c12-8fc0d4c8a315 | |
| relation.isAuthorOfPublication | 389fd122-e5b1-4a48-aad6-0594debe0b97 | |
| relation.isAuthorOfPublication.latestForDiscovery | 9a24b244-dd15-42a4-81de-9d5064152fb4 |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Alarcon_Ferroptosis_2025.pdf
- Size:
- 3.65 MB
- Format:
- Adobe Portable Document Format

